Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Gbathaton May 05, 2021 8:04am
123 Views
Post# 33130543

RE:RE:Explain This?

RE:RE:Explain This?My guess is that they want to be ready to meet demand when the news hits, or they have ongoing negotiations for non-exclusive licensing and don't want to front run a bigger PR by a bigger partner.

It looks to me like the test is ready to go into scale up mode, and the status of the test is as described in detail at COVID Imuunity Passports website. Otherwise that site would have been walled off in the same manner as immusafe.com . It is also possible that they decided the covid immunity passports website will be the main site instead of immusafe site. Especially given that other immusafe product that is out there.

Hopefully we get news soon.

RC, I had a similar opinion as you based on my due diligence regarding BCNI product status. Now I'm thinking it was being played down, given all the work they were doing with the corrections facility study.


<< Previous
Bullboard Posts
Next >>